XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 92.58

Change

-0.60 (-0.64)%

Market Cap

N/A

Volume

9.89M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.86 (-0.59%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.36 (-0.52%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.12 (-0.11%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.28%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.17 (-0.75%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.25 (+0.76%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.41 (-0.40%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.40 (-1.29%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.38 (-0.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.05 (-0.21%)

USD 6.89M

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

-0.08 (0%)

USD 0.06B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.80% 15% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.80% 15% F 59% D-
Trailing 12 Months  
Capital Gain 5.89% 48% F 50% F
Dividend Return 0.15% 19% F 1% F
Total Return 6.04% 48% F 39% F
Trailing 5 Years  
Capital Gain 3.88% 24% F 49% F
Dividend Return 0.53% 26% F 2% F
Total Return 4.41% 19% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain -2.22% 14% F 22% F
Dividend Return -2.15% 14% F 13% F
Total Return 0.08% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 31.09% 19% F 34% F
Risk Adjusted Return -6.90% 14% F 16% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.